Public Assessment Report. Decentralised Procedure
|
|
- Dwayne Jennings
- 7 years ago
- Views:
Transcription
1 Public Assessment Report Decentralised Procedure Thorens I.U. /ml oral drops, solution Thorens I.U. /2.5 ml oral solution Deltius I.U. /ml oral drops, solution Deltius I.U. /2.5 ml oral solution Cholecalciferol (Vitamin D 3 ) Procedure No: UK Licence No: PL 13297/ Italfarmaco S.p.A. 1
2 LAY SUMMARY On 27 August 2013, the Medicines and Healthcare products Regulatory Agency (MHRA) granted Marketing Authorisations to Italfarmaco S.p.A. for the medicinal products Thorens/Deltius I.U. /ml oral drops, solution (PL 13297/0001 and 0003; UK/H/ /001/DC) and Thorens/Deltius I.U. /2.5 ml oral solution (PL 13297/0002 and 0004; UK/H/ /002/DC). These are prescription-only medicines (POM). The products may be referred to as Thorens/Deltius oral drops, solution and oral solution in this report. Thorens/Deltius oral drops, solution and oral solution contain the active ingredient, cholecalciferol (vitamin D 3 ). Vitamin D can be found in some foods and is also produced by the body when skin is exposed to sunlight. Vitamin D inhibits the excretion of calcium by the kidneys and it stimulates the absorption of calcium in the intestine and it helps build bones. Thorens/Deltius oral drops, solution and oral solution are used: to prevent vitamin D deficiency when there is a significant risk of deficiency or an increased demand for vitamin D; with other medicines to treat certain bone conditions, such as thinning of the bone (osteoporosis); to treat vitamin D deficiency that has been confirmed by laboratory tests. No new or unexpected safety concerns arose from these applications and it was therefore judged that the benefits of taking Thorens/Deltius oral drops, solution and oral solution outweigh the risks, and Marketing Authorisations were granted. 2
3 TABLE OF CONTENTS Module 1: Information about the initial procedure Page 4 Module 2: Summary of Product Characteristics Page 5 Module 3: Patient Information Leaflet Page 6 Module 4: Labelling Page 7 Module 5: Scientific discussion during initial procedure Page 13 I Introduction II About the product III Scientific overview and discussion III 1 Quality aspects III 2 Non-clinical aspects III 3 Clinical aspects IV Overall conclusion and benefit/risk assessment Module 6: Steps taken after initial procedure Page 19 3
4 Module 1 Information about the initial procedure Product Name UK/H/5176/001/DC: Thorens I.U. /ml oral drops, solution UK/H/5176/002/DC: Thorens I.U. /2.5 ml oral solution UK/H/5177/001/DC: Deltius I.U. /ml oral drops, solution UK/H/5177/002/DC: Deltius I.U. /2.5 ml oral solution Type of Application Well-established use, Article 10a Active Substance(s) Cholecalciferol (Vitamin D 3 ) Form(s) Strength MA Holder Reference Member State (RMS) Concerned Member States (CMS) Oral drops, solution and oral solution Oral drops, solution; 1 ml (50 drops) contains I.U. cholecalciferol (vitamin D 3 ), equivalent to 0.25 mg. 1 drop contains 200 I.U. cholecalciferol (vitamin D 3 ). Oral solution; 1 ml contains I.U. cholecalciferol (vitamin D 3 ), equivalent to 0.25 mg Italfarmaco S.p.A. Viale Fulvio Testi, Milano, Italy UK UK/H/5176/ /DC: Ireland and Belgium UK/H/5177/ /DC: Spain, France, Portugal and Greece Procedure Numbers Timetable Day August
5 Module 2 Summary of Product Characteristics In accordance with Directive 2010/84/EU, the Summaries of Product Characteristics (SmPCs) for products granted Marketing Authorisations at a national level are available on the MHRA website. 5
6 Module 3 Patient Information Leaflet In accordance with Directive 2010/84/EU, the Patient Information Leaflets (PILs) for products granted Marketing Authorisations at a national level are available on the MHRA website. 6
7 Module 4 Labelling 7
8 8
9 9
10 10
11 11
12 12
13 Module 5 Scientific discussion during initial procedure I INTRODUCTION Based on the review of the data on quality, safety and efficacy, the member states considered that the applications for Thorens/Deltius I.U. /ml oral drops, solution (PL 13297/0001 and 0003; UK/H/ /001/DC) and Thorens/Deltius I.U. /2.5 ml oral solution (PL 13297/0002 and 0004; UK/H/ /002/DC) could be approved. The products are prescription-only medicines (POM) and are indicated: for the prevention and treatment of vitamin D deficiency; as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency. The active ingredient, cholecalciferol (Vitamin D 3 ), is produced by the skin under ultraviolet B (UVB) irradiation of the precursor 7-dehydrocholesterol. Vitamin D 3 is then hydroxylated in the liver into 25- hydroxyvitamin D 3 (25(OH)D). A second hydroxylation takes place in the kidneys, where 25(OH)D is converted into 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D), the activated form of Vitamin D. Vitamin D supplementation may correct a deficiency of Vitamin D and increase intestinal absorption of calcium. The physiological role of Vitamin D is that of a regulator of calcium homeostasis, and of phosphate metabolism. Vitamin D acts to maintain normal concentrations of calcium and phosphate in plasma by (a) facilitating their absorption from the small intestine, (b) enhancing their mobilisation from bone, and (c) decreasing their excretion by the kidney. The applications were submitted using the Decentralised Procedure (DCP), with the UK as Reference Member State (RMS) with Ireland and Belgium (UK/H/5176/ /DC) and Spain, France, Portugal and Greece (UK/H/5177/ /DC) as Concerned Member States (CMS). The applications were submitted under Article 10a of Directive 2001/83/EC, as amended, claiming to be applications for products containing an active substance of well-established use. Cholecalciferol is a well-established active substance in a variety of different pharmaceutical presentations. Bibliographic literature data have been submitted to support these applications. No new non-clinical or clinical studies were conducted for these applications, which is acceptable given that these are bibliographic applications for products containing an active ingredient of well-established use. The RMS has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place at all sites responsible for the manufacture, assembly and batch release of these products. For manufacturing sites within the Community, the RMS has accepted copies of current manufacturer authorisations issued by inspection services of the competent authorities as certification that acceptable standards of GMP are in place at those sites. The RMS and CMS considered that the applications could be approved at the end of procedure (Day 210) on 07 August After a subsequent national phase, licences were granted in the UK on 27 August
14 II. ABOUT THE PRODUCT Name of the product in the Reference Member State Name(s) of the active substance(s) (INN) Pharmacotherapeutic classification (ATC code) Pharmaceutical form(s) and strength(s) UK/H/5176/001/DC: Thorens I.U. /ml oral drops, solution UK/H/5176/002/DC: Thorens I.U. /2.5 ml oral solution UK/H/5177/001/DC: Deltius I.U. /ml oral drops, solution UK/H/5177/002/DC: Deltius I.U. /2.5 ml oral solution Cholecalciferol (Vitamin D 3 ) Vitamin D and analogues, cholecalciferol (ATC code: A11CC05) Oral drops, solution; 1 ml (50 drops) contains I.U. cholecalciferol (vitamin D 3 ), equivalent to 0.25 mg 1 drop contains 200 I.U cholecalciferol (vitamin D 3 ) Oral solution; 1 ml contains I.U. cholecalciferol (vitamin D 3 ), equivalent to 0.25 mg Reference number(s) for the Decentralised Procedure Reference Member State (RMS) United Kingdom Concerned Member State (CMS) UK/H/5176/ /DC: Ireland and Belgium UK/H/5177/ /DC: Spain, France, Portugal and Greece Marketing Authorisation Number PL 13297/ Name and address of the Italfarmaco S.p.A. authorisation holder Viale Fulvio Testi, Milano, Italy III SCIENTIFIC OVERVIEW AND DISCUSSION III.1 QUALITY ASPECTS ACTIVE SUBSTANCE INN: Cholecalciferol (Vitamin D 3 ) Compendial name (Ph. Eur.) Cholecalciferol Chemical Name: (5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3β ol; 9,10-Secocholesta-5,7,10(19)-trien-3-ol, (3β,5Z,7E) Molecular formula: C 27 H 744 O Structure: Molecular mass: Appearance: White to almost white crystalline powder, practically odourless Solubility: Insoluble in water (less than 1 mg/l at 20 C), freely soluble in acetone, ethanol 96%, chloroform, ether and in fatty oils. Cholecalciferol is the subject of a European Pharmacopoeia monograph. 14
15 Synthesis of the active substance from the designated starting materials has been described adequately and appropriate in-process controls and intermediate specifications are applied. Satisfactory specification tests are in place for all starting materials and reagents and these are supported by relevant Certificates of Analysis. Appropriate proof-of-structure data have been supplied. All potential known impurities have been identified and characterised. An appropriate specification is provided for the active substance. Analytical methods have been validated appropriately and are satisfactory for ensuring compliance with the relevant specifications. Batch analysis data are provided that comply with the proposed specification. Satisfactory Certificates of Analysis have been provided for all working reference standards. Suitable specifications have been provided for all packaging used. The primary packaging has been shown to comply with current guidelines concerning contact with foodstuff. Appropriate stability data have been generated to support the retest period when stored in the proposed packaging. MEDICINAL PRODUCT Other Ingredient Refined olive oil is the only pharmaceutical excipient. Appropriate justification for the inclusion of this excipient has been provided. Refined olive oil complies with its respective European Pharmacopoeia monograph. A satisfactory Certificate of Analysis has been provided, showing compliance with the proposed specification. Refined olive oil does not contain materials of animal or human origin. No genetically modified organisms (GMO) have been used in the preparation of refined olive oil. Pharmaceutical Development The objective of the development programme was to formulate safe, efficacious, stable, oral drops, solutions and oral solutions of cholecalciferol. Suitable pharmaceutical development data have been provided for these applications. Manufacturing Process Satisfactory batch formulae have been provided for the manufacture of the products, along with an appropriate account of the manufacturing process. The manufacturing process has been validated with full production-scale batches and has shown satisfactory results. Control of Finished Product The finished product specifications are acceptable. Test methods have been described and have been validated adequately, as appropriate. Batch data have been provided that comply with the release specifications. Certificates of Analysis have been provided for all working reference standards used. Container-Closure System Thorens/Deltius I.U. /ml oral drops, solution are packaged in 20 ml amber Type III glass bottles intended for multidose use containing 10 ml of oral drops solution (corresponding to 500 drops), sealed with childproof polypropylene caps. The products are supplied with a dropper applicator cap with a colourless type II glass stem and polypropylene cap. Thorens/Deltius I.U. /ml oral drops, solution are packed with the Patient Information Leaflet into cardboard cartons, in packs containing 1 bottle and 1 dropper applicator cap. 15
16 Thorens/Deltius I.U. /2.5ml oral solution are packaged in 5 ml amber Type III glass bottles intended for single dose use containing 2.5 ml of oral solution, sealed with caps made of polypropylene and polyethylene. The product is packed with the Patient Information Leaflet into cardboard cartons, in pack sizes of 1 and 4 single dose bottles. Satisfactory specifications and Certificates of Analysis for the primary packaging material have been provided. All primary packaging is controlled to European Pharmacopoeia standards and complies with guidance concerning materials in contact with foodstuff. Stability of the Product Finished product stability studies were performed in accordance with current guidelines on batches of finished product in the packaging proposed for marketing. Based on the results, the following shelf lives and storage conditions have been accepted: Thorens/Deltius I.U. /ml oral drops, solution: a shelf life of 3 years for the unopened product and 6 months for the opened product, with the storage conditions Do not store above 30 C. Do not freeze or refrigerate. Keep the bottle in the outer carton in order to protect from light. Thorens/Deltius I.U. /2.5 ml oral solution: a shelf life of 4 years, with the storage conditions Do not store above 30 C. Do not freeze or refrigerate. Keep the bottle in the outer carton in order to protect from light. Suitable post approval stability commitments have been provided to continue stability testing on batches of finished product. Bioequivalence/Bioavailability A bioequivalence study was not necessary to support applications of this type. Summary of Product Characteristics (SmPC), Product Information Leaflets (PILs) and Labels The SmPCs, PILs and labels are satisfactory from a pharmaceutical perspective. A package leaflet has been submitted for Thorens I.U. /ml oral drops, solution to the MHRA along with results of consultations with target patient groups ( user testing ), in accordance with Article 59 of Council Directive 2001/83/EC, as amended. The results indicate that the package leaflet is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that the leaflet contains. User testing of the package leaflets for Deltius I.U. /ml oral drops, solution, Thorens I.U. /2.5 ml oral solution and Deltius I.U. /2.5 ml oral solution has been accepted based on the bridging reports provided, making reference to the successful user-testing of the parent PIL for Thorens I.U. /ml oral drops, solution. Marketing Authorisation Application (MAA) Forms The MAA forms are satisfactory from a pharmaceutical perspective. Expert Report (Quality Overall Summary) The quality overall summary has been written by an appropriately qualified person and is a suitable summary of the pharmaceutical aspects of the dossier. Conclusion The grant of Marketing Authorisations is recommended. 16
17 III.2 NON-CLINICAL ASPECTS The pharmacodynamic, pharmacokinetic and toxicological properties of cholecalciferol are well-known. No new non-clinical data have been submitted and none are required. The applicant s non-clinical expert report has been written by an appropriately qualified person and is satisfactory, providing an appropriate review of the relevant non-clinical pharmacology, pharmacokinetics and toxicology. A suitable justification has been provided for non-submission of an Environmental Risk Assessment. The grant of Marketing Authorisations is recommended. III.3 CLINICAL ASPECTS Clinical Pharmacololgy No new clinical pharmacology data have been submitted and none are required for applications of this type. The clinical pharmacology of cholecalciferol is well-known. Efficacy No new efficacy data have been submitted and none are required for applications of this type. The clinical efficacy of cholecalciferol is well-established. Safety No new safety data were supplied or required for these bibliographic applications. Safety is adequately reviewed in the clinical overview. The safety profile of cholecalciferol is well-known. Summaries of Product Characteristics (SmPCs), Patient Information Leaflets (PILs) and Labels The SmPCs, PILs and labels are acceptable from a clinical perspective. The PILs are consistent with the details in the SmPCs and in line with the current guidance. The labelling is in line with the current guidance. Clinical Expert Report (Clinical Overview) The clinical overview has been written by an appropriately qualified physician and is a suitable summary of the clinical aspects of the dossier. Pharmacovigilance System and Risk Management Plan The Pharmacovigilance System, as described by the MAH, fulfils the requirements and provides adequate evidence that the MAH has the services of a qualified person responsible for pharmacovigilance, and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country. Suitable justification has been provided for not submitting a Risk Management Plan for these applications. Conclusion The grant of Marketing Authorisations is recommended. IV OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT QUALITY The important quality characteristics of Thorens/Deltius 10,000 I.U. /ml oral drops, solution and Thorens/Deltius I.U. /2.5 ml oral solution are well-defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance. 17
18 NON-CLINICAL No new non-clinical data were submitted and none are required for applications of this type. A non-clinical overview has been provided by an appropriately qualified person that consists of a review of the published literature. EFFICACY No new clinical data were submitted and none were required for applications of this type. The published literature supports the efficacy of the products in the proposed indications. The efficacy of cholecalciferol is well-known. The presented evidence for well-established use of the active substance is sufficient. SAFETY The safety profile of cholecalciferol is well-known. The literature review identified no new or unexpected safety issues or concerns. PRODUCT LITERATURE The approved SmPCs are satisfactory. The PILs and labelling are satisfactory, and consistent with the approved SmPCs. BENEFIT/RISK ASSESSMENT The quality of the products is acceptable, and no new non-clinical or clinical safety concerns have been identified. Cholecalciferol is a well-known active substance. Extensive clinical experience with cholecalciferol is considered to have demonstrated the therapeutic value of the compound. The benefit/risk balance is therefore considered to be positive. 18
19 Module 6 STEPS TAKEN AFTER INITIAL PROCEDURE - SUMMARY Date submitted Application type Scope Outcome 19
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Olopatadine Zentiva 1 mg/ml eye drops, solution (olopatadine hydrochloride) Procedure No: UK Licence No: PL 17780/0568 Winthrop Pharmaceuticals UK Limited
More informationPublic Assessment Report
Public Assessment Report Decentralised Procedure Zoledronic Acid 4mg/5ml Concentrate for Solution for Infusion Procedure No: UK Licence No: PL 24598/0029 Noridem Enterprises Limited LAY SUMMARY On 25 January
More informationPL 17871/0208 UKPAR TABLE OF CONTENTS
Fultium-D 3 3,200 IU Capsules PL 17871/0208 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure FOSFOMYCIN 3G GRANULES FOR ORAL SOLUTION Procedure No: UK Licence No: PL 31513/0007 Temapharm Sp. z.o.o. LAY SUMMARY On 17 April 2013, Czech Republic, Estonia,
More informationLacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report
Lacidipine 2 mg Film-Coated Tablets PL 08553/0502 Lacidipine 4 mg Film-Coated Tablets PL 08553/0503 UK Public Assessment Report TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure TELMISARTAN DR REDDY S 20 MG TABLETS TELMISARTAN DR REDDY S 40 MG TABLETS TELMISARTAN DR REDDY S 80 MG TABLETS (telmisartan) Procedure No: UK/H/5034/001-003/DC
More informationHYDROCORTISONE 10 MG TABLETS
HYDROCORTISONE 10 MG TABLETS (Hydrocortisone) PL 20072/0238 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation summary
More informationPublic Assessment Report. UK National Procedure. (colecalciferol) PL 16508/0047 PL 16508/0048. ProStrakan Ltd.
Public Assessment Report UK National Procedure STEXEROL-D 3 1,000 IU FILM-COATED TABLETS STEXEROL-D 3 25,000 IU FILM-COATED TABLETS (colecalciferol) PL 16508/0047 PL 16508/0048 ProStrakan Ltd. 1 LAY SUMMARY
More informationPublic Assessment Report. Decentralised Procedure. Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated. Sildenafil citrate UK/H/4855/001-3/DC
Public Assessment Report Decentralised Procedure Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated Sildenafil citrate UK licence no: PL 08553/0468-70 DR Reddy s Laboratories (UK) Limited 1 LAY SUMMARY
More informationDonepezil hydrochloride 10 mg film-coated tablets PL 19156/0130
Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics
More informationMemantine hydrochloride 20 mg film-coated tablets PL 17907/0291
Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of Product Characteristics
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Linezolid 2 mg/ml solution for infusion Linezolid 600mg film coated tablets Linezolid 100mg/5ml granules for oral suspension Procedure No: UK Licence No:
More informationPublic Assessment Report. Decentralised Procedure PARACETAMOL 1000 MG TABLETS. Procedure No: UK/H/5004/01/DC. UK Licence No: PL 18866/0060
Public Assessment Report Decentralised Procedure PARACETAMOL 1000 MG TABLETS Procedure No: UK Licence No: PL 18866/0060 Rockspring Healthcare Ltd LAY SUMMARY On 17 January 2013 the Medicines and Healthcare
More informationPublic Assessment Report. Decentralised Procedure. Cefadroxil 250 mg/5 ml granules for oral. (Cefadroxil monohydrate)
Public Assessment Report Decentralised Procedure Cefadroxil 250 mg/5 ml granules for oral suspension (Cefadroxil monohydrate) UK licence no: PL 34088/0033 Alkaloid-INT d.o.o. 1 Cefadroxil 250 mg/5 ml granules
More informationAciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR
Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for
More informationTRAMADOL HYDROCHLORIDE AND PARACETAMOL 37.5 MG/325 MG FILM-COATED TABLETS (tramadol hydrochloride and paracetamol ) PL 30684/0222 UKPAR
TRAMADOL HYDROCHLORIDE AND PARACETAMOL 37.5 MG/325 MG FILM-COATED TABLETS (tramadol hydrochloride and paracetamol ) PL 30684/0222 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure BOSENTAN ZENTIVA 62.5 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 125 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 62.5 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 125
More informationPublic Assessment Report
Public Assessment Report Decentralised Procedure Alendronic Acid and Calcium/Cholecalciferol 70+1000mg/880IU Film-coated Tablets+Effervescent Tablets Procedure No: UK Licence No: PL 04416/1162-4 Sandoz
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure TRIAMCINOLONE HEXACETONIDE 20 MG/ML SUSPENSION FOR INJECTION (triamcinolone hexacetonide) Procedure No: UK Licence No: PL 17509/0061 Intrapharm Laboratories
More informationPublic Assessment Report
Public Assessment Report Decentralised Procedure Ibuprofen and phenylephrine hydrochloride 200mg/5mg film-coated tablets Procedure No: UK Licence No: PL 17780/0563 Winthrop Pharmaceuticals UK Limited LAY
More informationRILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS
RILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Steps taken after authorisation summary
More informationPublic Assessment Report. Decentralised Procedure. Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution
Public Assessment Report Decentralised Procedure Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution (ipratropium bromide monohydrate) Procedure No: UK Licence No: PL
More informationIbuprofen 200mg Soft Capsules PL 03105/0105 UKPAR
Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 13 Summary of Product Characteristics Page 14 Patient
More informationANASTROZOLE 1 MG FILM-COATED TABLETS. (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS
ANASTROZOLE 1 MG FILM-COATED TABLETS (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics
More informationSTREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES
STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES (amylmetacresol, 2,4-dichlorobenzyl alcohol, ascorbic acid and sodium ascorbate) PL 00063/0692 UKPAR TABLE
More informationLevonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044
Levonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure IMATINIB TEVA UK 100 MG FILM-COATED TABLETS IMATINIB TEVA UK 400 MG FILM-COATED TABLETS (imatinib mesilate) Procedure No: UK Licence No: PL 00289/1516-1517
More informationPublic Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules
Public Assessment Report Scientific discussion Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules (calcium carbonate and cholecalciferol) NL License RVG: 111783 Date: 12 March 2015 This
More informationMIGRAINE RELIEF 342 MG FILM-COATED TABLETS PL 20154/0030 UKPAR TABLE OF CONTENTS
MIGRAINE RELIEF 342 MG FILM-COATED TABLETS PL 20154/0030 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 13 Steps taken after authorisation summary
More informationMACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS
MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps
More informationPublic Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o.
Public Assessment Report UKPAR Levonorgestrel 1.5 mg tablet (levonorgestrel). UK Licence No: PL 41947/0006 ELC Group s.r.o. 1 LAY SUMMARY Levonorgestrel 1.5 mg tablet (Levonorgestrel, tablet, 1.5 mg) This
More informationPublic Assessment Report. Decentralised Procedure. Omega 3-acid-ethyl esters 1000mg Soft Capsules. Omega-3-acid ethyl esters 90
Public Assessment Report Decentralised Procedure Omega 3-acid-ethyl esters 1000mg Soft Capsules Omega-3-acid ethyl esters 90 Procedure No: UK Licence No: PL 00289/1756 and PL 00289/1778-80 Teva UK Limited
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Levetiracetam 250 mg film-coated tablets PL 36390/0168; UK/H/5630/001/DC Levetiracetam 500 mg film-coated tablets PL 36390/0169; UK/H/5630/002/DC Levetiracetam
More informationFexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS
Fexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps
More informationAscorbic Acid 50 mg Tablets. Ascorbic Acid 100 mg Tablets. Ascorbic Acid 200 mg Tablets. Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287
Ascorbic Acid 50 mg Tablets Ascorbic Acid 100 mg Tablets Ascorbic Acid 200 mg Tablets Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287 PL 20416/0288 PL 20416/0289 UKPAR TABLE OF CONTENTS Lay Summary
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure PERRIGO PARACETAMOL/GUAIFENESIN/PHENYLEPHRINE HYDROCHLORIDE 500 MG/200 MG/10 MG POWDER FOR ORAL SOLUTION UK Licence No: PL 12063/0118 WRAFTON LABORATORIES
More informationOmeprazole 20 mg gastro-resistant tablets PL 14017/0277
Omeprazole 20 mg gastro-resistant tablets PL 14017/0277 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation
More informationCETIRIZINE DIHYDROCHLORIDE 10MG FILM-COATED TABLETS PL 40378/0140-1 UKPAR TABLE OF CONTENTS
CETIRIZINE DIHYDROCHLORIDE 10MG FILM-COATED TABLETS PL 40378/0140-1 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 8 Steps taken after authorisation
More informationPublic Assessment Report. Decentralised Procedure. Cefuroxime 250mg and 500mg film-coated tablets. Cefuroxime 500mg film-coated tablets
Public Assessment Report Decentralised Procedure Cefuroxime 250mg film-coated tablets Cefuroxime 500mg film-coated tablets Procedure No: UK Licence No: PL 35646/0020-0021 Alkem Pharma GmbH 1 LAY SUMMARY
More informationPublic Assessment Report. Decentralised Procedure. Tenofovir Zentiva 245 mg Film-coated Tablets. Tenofovir disoproxil fumarate UK/H/4970/001/DC
Public Assessment Report Decentralised Procedure Tenofovir Zentiva 245 mg Film-coated Tablets Tenofovir disoproxil fumarate UK licence no: PL 17780/0573 Winthrop Pharmaceuticals UK Limited 1 LAY SUMMARY
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Amlodipine Pfizer 5 mg tablets Amlodipine Pfizer 10 mg tablets Amlodipine Pfizer 5 mg hard capsules Amlodipine Pfizer 10 mg hard capsules Procedure No:
More informationPublic Assessment Report. Scientific discussion. Paracetamol Orifarm 500 mg film-coated tablets. (Paracetamol) DK/H/2271/001/DC.
Public Assessment Report Scientific discussion Paracetamol Orifarm 500 mg film-coated tablets (Paracetamol) DK/H/2271/001/DC 15 October 2014 This module reflects the scientific discussion for the approval
More informationPublic Assessment Report. (Budesonide) PL 17901/0254. AstraZeneca UK Ltd
Public Assessment Report Rhinocort Hay Fever 64 micrograms, Nasal Spray (Budesonide) PL 17901/0254 AstraZeneca UK Ltd 1 LAY SUMMARY Rhinocort Hay Fever 64 micrograms, Nasal Spray (Budesonide) This is a
More informationPublic Assessment Report. Decentralised Procedure. Alimemazine tartrate 7.5mg/5ml Syrup. Alimemazine tartrate 30mg/5ml Syrup
Public Assessment Report Decentralised Procedure Alimemazine tartrate 7.5mg/5ml Syrup Alimemazine tartrate 30mg/5ml Syrup Procedure No: UK Licence No: PL 41830/0029-0030 NRIM Limited 1 LAY SUMMARY Alimemazine
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Levodopa/Carbidopa/Entacapone Torrent 50 mg/12.5 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Torrent, 75 mg/18.75 mg/200 mg film-coated
More informationPublic Assessment Report. UK National Procedure. Perindopril 2 mg Tablets. Perindopril 4 mg Tablets. Perindopril 8 mg Tablets PL 20075/0294-0296
Public Assessment Report UK National Procedure Perindopril 2 mg Tablets Perindopril 4 mg Tablets Perindopril 8 mg Tablets PL 20075/0294-0296 Accord Healthcare Limited 1 LAY SUMMARY This is a summary of
More informationHypromellose Eye Drops BP 0.3% w/v PL 23097/0006
Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient
More informationPublic Assessment Report. Decentralised Procedure. CosmoCol Half 6.9 g, powder for oral solution CosmoCol Paediatric 6.9 g, powder for oral solution
Public Assessment Report Decentralised Procedure CosmoCol Half 6.9 g, powder for oral solution CosmoCol Paediatric 6.9 g, powder for oral solution (Macrogol, sodium chloride, sodium hydrogen carbonate
More informationCETRABEN ORIGINAL EMOLLIENT CREAM (PL 06831/0262) UKPAR TABLE OF CONTENTS
CETRABEN ORIGINAL EMOLLIENT CREAM (PL 06831/0262) UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation summary Page
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Levodopa/Carbidopa/Entacapone Accord 100 mg/25 mg/200 mg Film-coated tablets Levodopa/Carbidopa/Entacapone Accord 150 mg/37.5 mg/200 mg Film-coated tablets
More informationMontelukast 10mg film-coated tablets PL 17907/0474
Montelukast 10mg film-coated tablets PL 17907/0474 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation Page
More informationDecentralised Procedure. Public Assessment Report. Paracetamol-ratiopharm 10 mg/ml Infusionslösung Paracetamol DE/H/1908/001/DC
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Paracetamol-ratiopharm 10 mg/ml Infusionslösung Paracetamol DE/H/1908/001/DC Applicant: TEVA Pharma
More informationDEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314
DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics
More informationLEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES. (paracetamol, caffeine and phenylephrine hydrochloride)
LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES (paracetamol, caffeine and phenylephrine hydrochloride) PL 00063/0529 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Summary of
More informationBeclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178
Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 11 Steps Taken
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Paracetamol 500 mg effervescent tablets Procedure No: UK/H/5662/001-002/DC UK Licence No: PL 36390/0177-0178 Cipla (EU) Limited Lay Summary Paracetamol
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Atorvastatin 10 mg film-coated Tablets Atorvastatin 20 mg film-coated Tablets Atorvastatin 40 mg film-coated Tablets Atorvastatin 80 mg film-coated Tablets
More informationPublic Assessment Report Scientific discussion. Prednisolon mibe (prednisolone acetate) SE/H/1317/01/DC
Public Assessment Report Scientific discussion Prednisolon mibe (prednisolone acetate) SE/H/1317/01/DC This module reflects the scientific discussion for the approval of Prednisolon mibe. The procedure
More informationPublic Assessment Report UKPAR
Public Assessment Report UKPAR Amitriptyline 10 mg film-coated tablets Amitriptyline 25 mg film-coated tablets Amitriptyline 50 mg film-coated tablets (Amitriptyline hydrochloride) UK Licence No: PL 17907/0131-133
More informationPUBLIC ASSESSMENT REPORT. Decentralised Procedure DE/H/2924/001/DC. Calcium 1000 mg / Vitamin D3 880 I.U. chewable tablets
Federal Institute for Drugs and Medical Devices PUBLIC ASSESSMENT REPORT Decentralised Procedure DE/H/2924/001/DC Calcium 1000 mg / Vitamin D3 880 I.U. chewable tablets Calcium carbonate, Cholecalciferol
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure LANSOPRAZOLE 15 MG AND 30 MG ORODISPERSIBLE TABLETS (lansoprazole) Procedure No: UK Licence No: PL 35507/0118-0119 Lupin (Europe) Limited LAY SUMMARY Lansoprazole
More informationDecentralised Procedure. Public Assessment Report
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report ben-u-ron direkt Erdbeer/Vanille 250/500 mg Granulat in Beuteln ben-u-ron direkt Cappuccino 500/1000
More informationUrostemol Men capsules THR 02855/0240
Urostemol Men capsules THR 02855/0240 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 14 Steps taken after initial registration Page 15 Summary of
More informationPublic Assessment Report. Decentralised Procedure. PAR Bisoprolol 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg film-coated tabs
PAR Bisoprolol 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg film-coated tabs Public Assessment Report Decentralised Procedure Bisoprolol 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg film-coated
More informationCollege ter Beoordeling van Geneesmiddelen (CBG) Medicines Evaluation Board (MEB) Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands
MEB agency / Veterinary Medicinal Products Unit The Netherlands C B G M E B College ter Beoordeling van Geneesmiddelen (CBG) Medicines Evaluation Board (MEB) Graadt van Roggenweg 500 3531 AH Utrecht The
More informationArnicare Arnica 30c pillules NR 01175/0181 UKPAR
Arnicare Arnica 30c pillules NR 01175/0181 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of product characteristics Page 12 Product
More informationCollege ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands
College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY
More informationOMEPRAZOLE 10 MG, 20 MG AND 40 MG GASTRO-RESISTANT HARD CAPSULES. (omeprazole)
OMEPRAZOLE 10 MG, 20 MG AND 40 MG GASTRO-RESISTANT HARD CAPSULES (omeprazole) PL 36884/0001, PL 36884/0002, PL 36884/0003, PL 36884/0004, PL 36884/0005 AND PL 36884/0006 UKPAR TABLE OF CONTENTS Lay Summary
More informationPublic Assessment Report Scientific discussion. Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680
Public Assessment Report Scientific discussion Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680 This module reflects the scientific discussion for the approval of
More informationPublic Assessment Report. Scientific discussion. Desloracell 5 mg, film-coated tablet. (desloratadine) NL License RVG: 112807
Public Assessment Report Scientific discussion Desloracell 5 mg, film-coated tablet (desloratadine) NL License RVG: 112807 Date: 6 July 2015 This module reflects the scientific discussion for the approval
More informationDecentralised Procedure. Public Assessment Report
Decentralised Procedure Public Assessment Report Articainhydrochlorid mit Epinephrin Pierrel 40 mg/ml + 0.01 mg/ml Injektionslösung Articainhydrochlorid mit Epinephrin Pierrel 40 mg/ml + 0.005 mg/ml Injektionslösung
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Opticrom Allergy Single Dose 2% w/v Eye Drops, Solution (sodium cromoglicate) Procedure No: UK Licence No: PL 04425/0688 Aventis Pharma Limited (T/A Sanofi-aventis
More informationPhynova Joint and Muscle Relief Tablets THR 41783/0001 UKPAR
Phynova Joint and Muscle Relief Tablets THR 41783/0001 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Summary of Product Characteristics Page
More informationNEUROTONE THR 00904/0005 UKPAR
NEUROTONE THR 00904/0005 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Product Information Leaflet
More informationMucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665
Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient
More informationPublic Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no: 2013-0498
Public Assessment Report Scientific discussion Prednisolon Pilum (prednisolone) Asp no: 2013-0498 This module reflects the scientific discussion for the approval of Prednisolon Pilum. The procedure was
More informationPublic Assessment Report Scientific discussion. Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921
Public Assessment Report Scientific discussion Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921 This module reflects the scientific discussion for the approval of
More informationUKPAR Goodnight THR 00904/0003. Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS. Lay Summary Page 2. Scientific discussion Page 3
Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation Page 13 Summary of Product Characteristics
More informationDECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) Parque Empresarial Las Mercedes Edificio 8 C/ Campezo, 1 E - 28022 Madrid Spain (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY
More informationPublic Assessment Report. Scientific discussion. Apotel 10 mg/ml, solution for infusion. (paracetamol) NL/H/2857/001/DC
Public Assessment Report Scientific discussion Apotel 10 mg/ml, solution for infusion (paracetamol) NL/H/2857/001/DC Date: 16 December 2014 This module reflects the scientific discussion for the approval
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Linezolid Pfizer 2 mg/ml Solution for Infusion Linezolid Pfizer 100 mg/5 ml Granules for Oral Suspension Procedure No: UK/H/5515/001-003/DC UK Licence No:
More informationPublic Assessment Report Scientific discussion. Tenofovir disoproxil Teva (tenofovir disoproxil) SE/H/1432/01/DC
Public Assessment Report Scientific discussion Tenofovir disoproxil Teva (tenofovir disoproxil) SE/H/1432/01/DC This module reflects the scientific discussion for the approval of Tenofovir disoproxil Teva.
More informationPublic Assessment Report Scientific discussion. Levetiracetam Krka (Levetiracetam) SE/H/1067/01-04/DC
Public Assessment Report Scientific discussion Levetiracetam Krka (Levetiracetam) SE/H/1067/01-04/DC This module reflects the scientific discussion for the approval of Levetiracetam Krka. The procedure
More informationGuide to Fees for Veterinary Products
Guide to Fees for Veterinary Products FIN-G0003-14 04 FEBRUARY 2016 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS
More informationGinkgoforce Ginkgo biloba tablets THR 13668/0016 UKPAR
Ginkgoforce Ginkgo biloba tablets THR 13668/0016 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 13 Summary of product characteristics Page 14 Product
More informationVolume 2B Notice to Applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD)
Volume 2B Notice to Applicants Medicinal products for human use Presentation and format of the dossier Common Technical Document (CTD) Introduction Edition June 26 Module 1 Edition May 28 Module 2 Edition
More informationAgencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State)
DEPARTAMENTO DE MEDICAMENTOS VETERINARIOS Medicamentos y Productos C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR
More informationPublic Assessment Report. Scientific discussion. Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007
Public Assessment Report Scientific discussion Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007 Applicant: E Consult ApS, Denmark This module reflects the
More informationSomulose, 400 mg/25 mg/ml, Avlivningsvätska för djur Secobarbital Sodium. Applicant: Dechra Limited
NATIONAL PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Somulose, 400 mg/25 mg/ml, Avlivningsvätska för djur Secobarbital Sodium Applicant: Dechra Limited Postadress/Postal
More informationPublic Assessment Report. Scientific discussion. Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676. Applicant: E Consult ApS, Denmark
Public Assessment Report Scientific discussion Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676 Applicant: E Consult ApS, Denmark This module reflects the scientific discussion for the approval
More informationISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS
ISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Steps taken after authorisation
More informationPublic Assessment Report Scientific discussion. Tostrex (Testosterone) SE/H/571/01
Public Assessment Report Scientific discussion Tostrex (Testosterone) SE/H/571/01 This module reflects the scientific discussion for the approval of Tostrex. The procedure was finalised at 2006-04-07.
More informationSODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS
SODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Steps taken after authorisation
More informationSummary Public Assessment Report. Generics
Summary Public Assessment Report Generics 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public Assessment Report Generics Amoxicillin
More informationAgencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State)
DEPARTAMENTO DE MEDICAMENTOS VETERINARIOS Medicamentos y Productos C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State) DECENTRALISED PROCEDURE [DRAFT] PUBLICLY AVAILABLE ASSESSMENT REPORT
More informationSummary Public Assessment Report. Generics. Amoxicilina + Ácido Clavulânico Ranbaxy,
Summary Public Assessment Report Generics Amoxicilina + Ácido Clavulânico Ranbaxy 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public
More informationIbuprofen 10% w/w gel Nurofen Maximum Strength 10 % Gel
Ibuprofen 10% w/w gel Nurofen Maximum Strength 10 % Gel PL 10972/0089 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics
More informationHaving regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;
DIRECTIVE 65/65/EEC Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ L No 22 of
More informationGuideline on dossier requirements for Type IA and IB notifications
Guideline on dossier requirements for Type IA and IB notifications In accordance with Regulation (EC) No 726/2004 and Directives 2001/83/EC and 2001/82/EC, a common approach to the procedures for variations
More informationVoke 0.45mg Inhaler PL 39589/0001 Nicotine 0.45mg Inhaler PL 39589/0002 UKPAR TABLE OF CONTENTS
Voke 0.45mg Inhaler PL 39589/0001 Nicotine 0.45mg Inhaler PL 39589/0002 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps taken for assessment Page 40 Steps taken after authorisation
More information